Aviva Biopharm develops novel, targeted therapeutics by modernizing established hormone science, focusing initially on unmet needs in women's health. The company is creating first-in-class, non-aromatizing testosterone formulations specifically designed for women experiencing age-related hormonal decline. Their lead candidate aims to deliver the benefits of testosterone therapy while mitigating safety concerns associated with current treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Despite the established role of testosterone in women's health, there are no FDA-approved testosterone therapies specifically designed for this demographic. This gap leaves millions of women experiencing symptoms associated with declining testosterone levels, such as low libido, muscle loss, and fatigue, without targeted treatment options.
Solution
Aviva Bio is developing d3-Testosterone (AVA-291), a novel, first-in-class non-aromatizing testosterone therapy engineered for women. This therapeutic candidate retains the benefits of testosterone while mitigating the conversion to estradiol, addressing a key safety concern that has historically limited testosterone use in women. By focusing on this unmet medical need, Aviva Bio aims to provide a safe and effective treatment for conditions linked to low testosterone in menopausal women and beyond. The company is advancing AVA-291 through its development pipeline with the goal of achieving Phase III-ready status.
Target Audience
The primary target audience includes women experiencing symptoms of low testosterone, particularly during menopause, and healthcare providers specializing in women's health, endocrinology, and hormone therapy.
Features
- First-in-class non-aromatizing testosterone molecule (d3-Testosterone) designed for female physiology.
- Potential to deliver testosterone benefits without conversion to estradiol, addressing a known safety challenge.
- New chemical entity with robust U.S. patent protection.
- Targeted therapeutic approach for conditions associated with declining testosterone in women, including menopausal symptoms.